Get the Stockscreener App
100.30
1.84%
1.81
Rhythm Pharmaceuticals Inc stock is traded at $100.30, with a volume of 1.16M.
It is up +1.84% in the last 24 hours and up +0.47% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
See More
Previous Close:
$98.49
Open:
$96.55
24h Volume:
1.16M
Relative Volume:
1.86
Market Cap:
$6.66B
Revenue:
$136.86M
Net Income/Loss:
$-168.69M
P/E Ratio:
-35.69
EPS:
-2.81
Net Cash Flow:
$-113.49M
1W Performance:
-11.83%
1M Performance:
+0.47%
6M Performance:
+55.19%
1Y Performance:
+56.96%
1-Day Range:
$95.27
$102.20
1-Week Range:
$95.27
$114.19
52-Week Range:
$45.91
$116.00
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
100.30 | 6.57B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | Goldman | Buy |
| Jul-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Rhythm Pharmaceuticals stock dips as Goldman Sachs lowers price target - Investing.com India
Rhythm Pharmaceuticals stock dips as Goldman Sachs lowers price target By Investing.com - Investing.com UK
The Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Third-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
Rhythm Pharmaceuticals anticipates IMCIVREE launch in acquired hypothalamic obesity with $416M cash position - MSN
Can Rhythm Pharmaceuticals Inc. stock weather global recessionWeekly Profit Report & Verified Stock Trade Ideas - newser.com
US FDA extends review of Rhythm's drug for brain damage-related obesity - Reuters
Rhythm Pharmaceuticals stock falls after FDA extends review period By Investing.com - Investing.com Philippines
Rhythm Pharmaceuticals stock falls after FDA extends review period - Investing.com
Rhythm pharma down as FDA delays Imcivree label expansion - Seeking Alpha
US FDA extends review of Rhythm Pharma's drug for rare form of obesity - TradingView
Rhythm Pharmaceuticals Announces FDA Extension of PDUFA Goal Date for IMCIVREE® to March 20, 2026 - Quiver Quantitative
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE (setmelanotide) for Patients with Acquired Hypothalamic Obesity - TradingView
Rhythm Pharmaceuticals (Nasdaq: RYTM) PDUFA Set for Mar 20, 2026 as FDA Extends Review - Stock Titan
Is Rhythm Pharmaceuticals Inc. (1RV) stock supported by free cash flow2025 Momentum Check & Real-Time Chart Pattern Alerts - newser.com
What to do if you’re stuck in Rhythm Pharmaceuticals Inc.2025 Big Picture & Precise Entry and Exit Recommendations - newser.com
Is Rhythm Pharmaceuticals Inc. stock positioned for digital transformationEarnings Overview Report & Technical Entry and Exit Tips - newser.com
Rhythm Pharmaceuticals’ Revenue Leaps On Rare Disease Drug Sales - Finimize
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2025 Earnings Call Transcript - Insider Monkey
Can Rhythm Pharmaceuticals Inc. (1RV) stock hold up in economic slowdown2025 Retail Activity & Weekly Top Performers Watchlists - fcp.pa.gov.br
Can machine learning forecast Rhythm Pharmaceuticals Inc. recoveryEarnings Risk Summary & Smart Investment Allocation Insights - newser.com
How currency fluctuations impact Rhythm Pharmaceuticals Inc. stockJuly 2025 Big Picture & Community Consensus Trade Signals - newser.com
Why Rhythm Pharmaceuticals Inc. stock is in analyst buy zoneMarket Activity Summary & Low Risk High Win Rate Stock Picks - newser.com
Why retail investors favor Rhythm Pharmaceuticals Inc. stockWeekly Earnings Recap & Consistent Profit Trading Strategies - fcp.pa.gov.br
Published on: 2025-11-06 01:43:02 - newser.com
Is Rhythm Pharmaceuticals Inc. reversing from oversold territoryWeekly Trade Report & Technical Confirmation Trade Alerts - newser.com
Visualizing Rhythm Pharmaceuticals Inc. stock with heatmapsRisk Management & Real-Time Volume Analysis Alerts - newser.com
Can Rhythm Pharmaceuticals Inc. stock deliver surprise earnings beatPortfolio Return Summary & Real-Time Market Trend Scan - fcp.pa.gov.br
What analysts say about Rhythm Pharmaceuticals Inc 1RV stockMomentum Trading Signals & Exceptional Return Stocks - earlytimes.in
Rhythm Pharmaceuticals (RYTM): Losses Have Averaged 18.8% Growth Annually; Revenue Forecast +45.8% Heading Into Earnings - Yahoo Finance
Will Rhythm Pharmaceuticals Inc. stock deliver shareholder valueQuarterly Portfolio Summary & Low Risk Entry Point Guides - fcp.pa.gov.br
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program - The Manila Times
Rhythm Pharma (NASDAQ: RYTM) secures IMCIVREE coverage in 5 provinces and NIHB for BBS - Stock Titan
Rhythm Pharmaceuticals, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:RYTM) 2025-11-05 - Seeking Alpha
Rhythm Pharmaceuticals Shares Fall After Oppenheimer Downgrade - MarketScreener
Rhythm Pharmaceuticals Inc (RYTM) Stock Price, Trades & News - GuruFocus
Needham & Company LLC Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Down Following Weak Earnings - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Posts Quarterly Earnings Results, Misses Estimates By $0.10 EPS - MarketBeat
Freestone Capital Holdings LLC Purchases New Stake in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Real time alert setup for Rhythm Pharmaceuticals Inc. performanceAnalyst Downgrade & Weekly Setup with ROI Potential - newser.com
Rhythm Pharmaceuticals Reports Q3 2025 Financial Results - TipRanks
Will Rhythm Pharmaceuticals Inc. price bounce be sustainableMarket Performance Report & Stock Portfolio Risk Control - newser.com
Transcript : Rhythm Pharmaceuticals, Inc., Q3 2025 Earnings Call, Nov 04, 2025 - MarketScreener
Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Sells $1,123,359.52 in Stock - MarketBeat
How resilient is Rhythm Pharmaceuticals Inc. stock in market downturnsCPI Data & Accurate Technical Buy Alerts - newser.com
Needham Maintains Rhythm Pharmaceuticals (RYTM) Buy Recommendation - Nasdaq
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):